Institute of Medical Microbiology, University of Zurich, Zurich, Switzerland.
Linkster Therapeutics AG, Zurich, Switzerland.
Nat Protoc. 2020 May;15(5):1707-1741. doi: 10.1038/s41596-020-0304-x. Epub 2020 Apr 8.
Here, we provide a protocol to generate synthetic nanobodies, known as sybodies, against any purified protein or protein complex within a 3-week period. Unlike methods that require animals for antibody generation, sybody selections are carried out entirely in vitro under controlled experimental conditions. This is particularly relevant for the generation of conformation-specific binders against labile membrane proteins or protein complexes and allows selections in the presence of non-covalent ligands. Sybodies are especially suited for cases where binder generation via immune libraries fails due to high sequence conservation, toxicity or insufficient stability of the target protein. The procedure entails a single round of ribosome display using the sybody libraries encoded by mRNA, followed by two rounds of phage display and binder identification by ELISA. The protocol is optimized to avoid undesired reduction in binder diversity and enrichment of non-specific binders to ensure the best possible selection outcome. Using the efficient fragment exchange (FX) cloning method, the sybody sequences are transferred from the phagemid to different expression vectors without the need to amplify them by PCR, which avoids unintentional shuffling of complementary determining regions. Using quantitative PCR (qPCR), the efficiency of each selection round is monitored to provide immediate feedback and guide troubleshooting. Our protocol can be carried out by any trained biochemist or molecular biologist using commercially available reagents and typically gives rise to 10-30 unique sybodies exhibiting binding affinities in the range of 500 pM-500 nM.
在这里,我们提供了一个方案,可在 3 周内针对任何纯化的蛋白质或蛋白质复合物生成合成纳米抗体,即 sybodies。与需要动物来产生抗体的方法不同,sybody 的选择完全在体外控制的实验条件下进行。这对于针对不稳定的膜蛋白或蛋白质复合物生成构象特异性结合物特别重要,并且允许在非共价配体存在下进行选择。sybodies 特别适合由于靶蛋白的高序列保守性、毒性或稳定性不足而导致通过免疫文库生成结合物失败的情况。该方案涉及一轮核糖体展示,使用由 mRNA 编码的 sybody 文库,然后进行两轮噬菌体展示和通过 ELISA 进行结合物鉴定。该方案经过优化,可避免结合物多样性的不必要减少和非特异性结合物的富集,以确保尽可能好的选择结果。使用有效的片段交换 (FX) 克隆方法,可将 sybody 序列从噬菌粒转移到不同的表达载体,而无需通过 PCR 扩增它们,从而避免互补决定区的意外改组。使用定量 PCR(qPCR),可监测每个选择轮的效率,以提供即时反馈并指导故障排除。我们的方案可以由任何经过培训的生物化学家和分子生物学家使用商业上可获得的试剂进行,通常会产生 10-30 种独特的 sybody,其结合亲和力在 500 pM-500 nM 范围内。